Introduction
A primary aim of lung transplantation (LT) is to improve health-related quality of life (HRQL) for persons suffering from advanced lung disease. This is especially true in situations in which the decision to transplant is not clear, for example in older candidates (aged 65 or more) whose median survival after transplant is only 3.5 years or for even younger persons with conditions such as chronic obstructive pulmonary disease (COPD) for which an absolute survival benefit from transplant is uncertain (1, 2) . Accurate assessment of the effect of LT on HRQL is fundamental to making informed clinical decisions and gauging more comprehensively the personalized "net-benefit" of transplant.
In 2005, organ allocation policy in the United States was overhauled to one driven by urgency of need. The resultant Lung Allocation Score (LAS) sought to maximize "transplant benefit" by reducing waitlist mortality without negatively impacting 1-year postoperative survival (3) . The LAS policy-along with advances in bridging the critically ill to transplant (4,5)-shifted lung allocation to older, sicker patients. Compared to 4% in 2002, patients aged ≥65, for example, account now for 30% of new U.S. transplant recipients (6) . Morbidity and mortality after the first postoperative year have also increased in this period (7, 8) .
Much of the contemporary literature relevant to this topic has focused on important individual domains of health that are influential determinants of HRQL, such as depression, anxiety, cognitive function, and functional status (9) (10) (11) (12) (13) (14) (15) (16) . Nonetheless, relatively few studies focused on HRQL itself as a primary outcome in LT have been published since the LAS overhaul (23) . Thus, given the clinical primacy of HRQL, there is a need for contemporary information on the effect of LT on general and respiratory-specific HRQL.
We aimed to comprehensively evaluate the effect of LT on HRQL in an adult U.S. cohort undergoing transplant under the LAS allocation system. Beginning before LT, we followed subjects for up to 3 years after surgery. We evaluated HRQL over a spectrum of ages and disease groups using multiple measures including generic HRQL, respiratory-specific HRQL, and health utility instruments. We also evaluated the extent to which changes in BMI, allograft function, and exercise capacity affect HRQL over time. Finally, we examined the extent to which changes in HRQL are accounted for by improvements in physical disability. Preliminary results have been reported in abstracts and in a manuscript based on our initial recruitment experience (24) (25) (26) (27) (28) (29) (30) .
Methods

Study design, participants, and setting
We performed this study among participants in the University of California San Francisco "Breathe Again" study, an ongoing prospective cohort study of English-speaking adults (age ≥18) undergoing first-time LT and able to read, write, and complete structured survey batteries. Initiated in February 2010, Breathe Again aims to study the effect of LT on patientcentered outcomes, including HRQL, and to identify pulmonary and extrapulmonary determinants of these outcomes.
Adults with advanced lung disease are enrolled at the time of placement on the waitlist for LT. At enrollment, we perform a structured research visit that includes a structured survey battery to ascertain HRQL by multiple measures. Participant self-assessed disability is determined at the same time. Quantitative functional assessments include the 6-minute walk distance (6MWD) as well as selected other measures of physical performance. Research visits are conducted in the hospital if study participants are inpatients at the time of listing. While waitlisted, assessments are repeated quarterly; the data most proximal to the date of transplant are treated as the pretransplant baseline values for analytic purposes. The same survey and physical assessments are administered at 3 and 6 months after transplantation and semiannually thereafter for up to 3 years. To minimize selection bias, home or in-hospital visits are conducted within 1 month of the planned study visit if subjects cannot attend the outpatient study facility or miss a study visit due to illness or other reasons. Follow-up continued through May 12, 2016 . The University of California, San Francisco Committee on Human Research approved the study and written informed consent was obtained from all study participants.
Clinical eligibility for LT continues to evolve at UCSF. During the study period (and at the time of this report), our program considers adults up to the age of 75 years for LT. Given the heightened risk of mortality after transplant for older candidates, use of extracorporeal membrane oxygenation (ECMO) is currently restricted to candidates aged 65 or younger. In general, immunosuppressive and infection prophylaxis strategies after transplant are applied uniformly across age and diagnostic groups.
More detailed descriptions of the multiple HRQL instruments' properties, a conceptual model of disablement, and analytic approaches may be found in the online supplemental materials.
Outcome variables: HRQL
By definition, HRQL is multidimensional (31) . To evaluate generic HRQL we utilized the Medical Outcomes Survey Short Form-12 version 2 (SF12) Physical and Mental Component Summary scores (SF12-PCS and -MCS, respectively; a change of 5 points is generally considered to meet criteria as the minimally clinically important difference [MCID] in HRQL) (32) (33) (34) . To evaluate respiratory-specific HRQL, we utilized the Airways Questionnaire 20-Revised (AQ20-R; MCID: 1.75) (35) . To measure health utility, we administered the Euroqol 5D 3L (EQ5D; MCID: 0.06) and Visual Analog Scale (EQVAS; MCID: 10) (36-38). Higher scores indicate better health status.
Confounding and predictor variables
We were interested in evaluating the relative association of changes in commonly evaluated clinical measures of transplant efficacy with HRQL. A conceptual model of disablement first proposed by Nagi and later adapted by the Institute of Medicine informed our variable selection (Figure 1 ; Data S1) (39, 40) . In this model, pathology leads to functional limitations, which are easily quantifiable actions (e.g. distance walked in 6 min). Functional limitations lead to disability, defined as performing activities in daily life (e.g. walking to the grocery store). In this model, disability is an upstream precursor to and determinant of both HRQL and mortality. 
Disability
HRQL in LT is a multidimensional patient-centered outcome that has many contributors. Among these, physical functioning is particularly Nagi (43) , the pathway begins with a disease process that causes organ pathology. As this pathology becomes clinically relevant, organ dysfunction emerges, termed impairment. Impairment, in turn, leads to reductions in actions, termed functional limitations. Functional limitations may then lead to disability, defined as difficulty performing activities in daily life. Disability is an upstream precursor to and determinant of both health-related quality of life (HRQL) and mortality.
important (12, 41, 42) . Indeed, patients often cite impairment in physical functioning as a primary motivation for considering LT. Physical disability can impact activities extending far beyond activities of daily living. These activities can include, for example, working or attending school as well as activities that many believe make life meaningful such as spending time with friends and family, other forms of social engagement, and traveling (43) . Although whether LT improves disability is, in and of itself, an important outcome, we hypothesized that some of the changes in HRQL LT affords may be accounted for by improved physical disability. To quantify disability across this broad range of activities, we used the Lung Transplant Valued Life Activities scale (LT-VLA) (28) . The LT-VLA is a 15-item validated measure of disability across the full spectrum of functioning in LT.
Analytic approach
Exploratory plots of HRQL over time identified the need for a piecewise longitudinal modeling approach. Based on visual inspection of the plots for each HRQL measure, "early" effects were defined as changes in HRQL from pretransplant baseline up to 3 months after transplantation; "delayed" effects were defined as changes from beyond 3 months after transplantation to completion of 3-year follow-up, death, dropout, or the end of the study period, whichever came first.
We estimated the effect of LT on HRQL using piecewise linear mixed models with random intercepts. To account for survivorship, HRQL was jointly modeled with death, which allows the HRQL component of the model to focus on subjects still living. By jointly modeling HRQL and death, the model is able to distinguish between observable missing HRQL (a subject who is alive but did not complete survey) and unobservable missing HRQL (a subject who has died). In Model 1, we included piecewise terms to allow for different coefficients for time (early vs. delayed), pretransplant age, sex, diagnostic group, LAS, BMI, FEV 1 , and 6MWD as fixed effects. Since the effect of LT on HRQL might vary based on age or disease indication, we performed secondary analyses stratified by age groups defined a priori (18-49, 50-64, 65+) with ordinal tests of trend and by diagnostic groups (COPD, pulmonary arterial hypertension, cystic fibrosis [CF] , and pulmonary fibrosis) with tests of differences. Model testing for each HRQL instrument demonstrated stability in the key parameter estimates of study interest whether including age and diagnostic group together or separately, thus supporting that there were no substantive issues with collinearity between these two variables. To determine the extent to which change in HRQL was mediated by improvements in disability, Model 2 added LT-VLA as a random effect to Model 1 and the difference in estimates was compared. We also supplementally checked our mediation modeling using a validated four-step method (44) .
To evaluate the effect of changes in BMI, FEV 1 , and 6MWD on changes in HRQL over the same time period, we utilized linear mixed models jointly modeled with death. We evaluated the univariate effect of each variable and then combined them in multivariate models. Changes in each variable were scaled to its clinically meaningful difference: 2.2 units for BMI (0.5 its standard deviation), 200 mL in FEV 1 , and 30 m in 6MWD.
Finally, given the importance of 1-year survival after LT, we determined the proportion of subjects who were alive but did not derive a HRQL benefit at 1 year from the date of transplant. We defined HRQL benefit as an improvement in magnitude at least twice its MCID, an approach previously taken in other major thoracic surgery (45) . We tested differences in baseline characteristics between those who improved and those who did not by Fisher's exact or Wilcoxon rank-sum tests. As a secondary analysis, we defined HRQL as an improvement in magnitude of one time its MCID and also determined the proportion of subjects whose HRQL worsened at 1 year compared to before transplant.
Not all subjects completed all study visits. While mixed models can handle occasional missing data, this advantage applies only to data missing at random. We deemed survey data to be missing at random if subjects did not complete surveys for reasons other than their health and, on review of their concurrent clinical status, were not hospitalized, had stable allograft function, and were not dealing with acute medical issues (e.g. missing data because the clinic appointment ran late and the subject needed to leave promptly to avoid traffic or if a coordinator was not available). Surveys were deemed missing not at random if subjects were too ill to complete the survey. As a sensitivity analysis, we assigned subjects with nonrandom missing data (including those who dropped out) the median of the lowest quartile of HRQL scores for all other participants at that time point.
We addressed survivorship through joint modeling rather than by other techniques such as assigning those who died the worst HRQL possible or imputation. This approach is more relevant to data intended for clinical counseling because it provides more accurate estimates of the effect of LT on HRQL for patients still living. It is less useful for estimating of the effect of transplant on population-level HRQL.
Uniquely, the EQ5D allows for explicit accounting for death by assigning those who died a score of 0, but allowing the living to self-rate their utility state even lower than that. As EQ5D-specific sensitivity analysis, we reanalyzed the effect of lung transplant on EQ5D by linear mixed models, assigning subjects a score of 0 for all time points following their date of death. It should be noted that this particular analytic approach provides population-level estimates of EQ5D HRQL than estimates relevant for patient-specific clinical counseling.
Analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
Results
Of the 228 patients eligible for this study, 17 declined to participate. Among the 211 subjects enrolled during the study period (93% consent rate), 46% were female; the median age, 58 years (interquartile range [IQR]: 48-64); and the median LAS, 45.2 (IQR: 37.8-64.7) ( Figure 2 ; Table 1 ). Of the cohort, 24% were aged 65 or older; 33% were already hospitalized at the time of transplantation (11% of the overall cohort were intubated and 9% received extracorporeal membrane oxygenation support). At baseline, older subjects reported better SF12-MCS and AQ-20R HRQL compared to younger subjects (p-values 0.01 and 0.005, respectively) but similar SF12-PCS, EQ5D, and EQ VAS-based HRQL. Over the study period, 6 subjects dropped out (3%), 31 died (14%), and 40 developed chronic lung allograft dysfunction (19%; [CLAD]) defined by a validated spirometry-based approach that considers both FEV 1 as well as forced vital capacity (46, 47) . The overall survey completion rate was 86%; rates ranged from 71% to 92% across time points (Table S1 ).
Generally, LT was associated with improvements in HRQL that achieved three to four times each instrument's MCID; the SF12-MCS was the exception for which improvements minimally exceeded its MCID (Table 2) . While improvements were generally observed by 3 months, improvements in SF12-PCS continued through 6 months ( Figure 3 ). After early improvements, HRQL was stable overall or declined by clinically negligible amounts in survivors for the remainder of the follow-up period. For example, on average, subjects experienced a 15-point improvement in SF12-PCS within the first 3 months after transplantation (95% CI, 13.4-16.7; MCID = 5). The decline thereafter was À0.2 points (95% CI, À0.4 to 0.05). Sensitivity analysis with imputed scores for missing surveys did not appreciably change these effect estimates (data not shown). Effect estimates for EQ5D were attenuated in analyses assigning subjects who died a score of 0, especially in older subjects (Tables 3, S2 , and S3).
A substantial proportion of the effect of LT on HRQL was accounted for by improvements in disability. After accounting for improvements in LT-VLA disability, LT was associated with improvements in SF12-PCS, AQ20-R, and EQVAS HRQL that reached only one to two times the MCID and the changes in SF12-MCS and EQ5D were no longer significant (Table 2 ).
Notable differences emerged in the age-stratified analyses. After controlling for diagnosis and other factors, older subjects (age ≥65) had substantially smaller improvements in generic HRQL compared to younger subjects (test of trend p-value = 0.05) ( Table 4 ). For the SF12-MCS, older subjects experienced no improvement, whereas those in the two younger strata improved by 1.5 times the MCID (test of differences p-value = 0.002). Although older subjects experienced smaller improvements in respiratoryspecific HRQL and health utility than younger subjects, these differences were not statistically significant.
Changes in HRQL differed significantly by condition in the diagnosis-stratified analyses (Table 5 ). After controlling for age and other cofactors, participants with CF experienced the largest improvements in HRQL across all measures (p ≤ 0.021). Improvements were generally similar in those with pulmonary fibrosis or COPD and were the smallest in pulmonary hypertension.
Next, we examined the effect of potential determinants of HRQL. Although statistically significant, changes in BMI, FEV 1 , and 6MWD did not independently explain a clinically relevant amount of the changes in HRQL (Table S4) . Although the absolute differences were small, improvement in FEV 1 was associated with larger point estimates of improvement in AQ20-R relative to BMI and 6MWD, whereas improvement in 6MWD was associated with larger improvements in EQ5D.
Finally, a substantial subset of subjects did not achieve improved HRQL 1 year after LT (Table 6 ). Depending on the metric, the proportion failing to improve by twice the MCID ranged from 11% to 60%. Across measures, there were inconsistent differences in baseline factors between those who improved and those who did not (Table 7) . In EQ5D, for example, those who improved had lower BMI, higher LAS scores, shorter 6MWD, and were hospitalized at the time of transplantation, whereas in AQ20-R those who did not improve had better pretransplant lung function. A relatively small proportion of subjects reported worse HRQL at 1 year after LT compared to before, most notably in SF12-MCS and EQ5D HRQL measures (Table S5) .
Discussion
In this study of the effect of LT in the era of the LAS, we found that LT delivers large and clinically meaningful improvements in HRQL to most adults with advanced lung disease. The improvements were generally three to four times the magnitude of what are considered to meet MCIDs. Furthermore, improvements were achieved within the first 6 months after surgery and were durable-among survivors-for up to 3 years. Amelioration in disability appeared to account for a substantial proportion of this improvement. Although all age groups and disease types experienced substantial HRQL gains, some (most notably, older persons) did not benefit to the same degree. Moreover, a subset of patients failed to improve to a clinically meaningful degree at the 1-year posttransplant mark and those who did not survive experienced a sharp fall-off in HRQL prior to death.
The durability of the improvements in generic and disease-specific HRQL in survivors was encouraging and somewhat surprising. Other studies (from the pre-LAS era) have identified a slow, relentless HRQL decline after the first postoperative year, although rarely declining to the low levels observed before LT (33, 48, 49) . Furthermore, we found that improvements were achieved within the first 3 postoperative months, which contrasts to prior studies that found improvements continuing through the first year (49,50).
Our findings have immediate clinical implications. These data provide information desired by patients considering LT today to make more fully informed decisions. Equally relevant, these data provide clinicians with information to guide counseling tailored to specific age and diagnostic groups. Also, given the increasingly common scenario of transplanting acutely ill patients, it is reassuring that patients hospitalized in the run-up to transplant have the same likelihood of improved HRQL as those who are called in from home.
Our study identifies other important issues. In our cohort, patients age 65 or older derived substantially less HRQL benefit than younger patients. It is known that patients older than 65 have a median survival time after LT of only 3.5 years: fully 3 years less than for patients younger than 50 (51) . We also found that routinely collected clinical measures, including BMI, lung function, and exercise capacity, did not explain a substantial degree of changes in HRQL. Higher baseline HRQL scores among older compared to younger subjects, which only differed statistically for two of the five measures, are unlikely to account for the smaller degree of improvement observed for that stratum across all the HRQL measures. Taken together, these findings identify the need for novel measures and approaches to deliver both improved HRQL and survival, especially to those of older age. Emerging work suggests that constructs relevant in older populations such as frailty, depression, and cognitive impairment may be important (10, 11, 19, 20) .
Importantly, our data should not be used to exclude older patients from LT for lack of benefit on an individual level. While they derived less benefit relative to younger patients, the benefits across measures were, nevertheless, two to three times what is considered to be minimally important. The benefit of LT in terms of HRQL also differed by diagnostic group, even after accounting for age. Reasons for this differential benefit are not clear. Efforts to understand why some groups, such as CF, derive larger benefits may inform interventions to improve HRQL in others (45,48,52). Our LT-VLA data and recent investigations focused on other individual health domains important in LT (e.g. depression and anxiety (9, 10, 14, 19, 21) , physical functioning/disability (12, 17, 28) , symptom burden (16, 18) , and cognitive impairment (13, 15, 22) ) suggest that increased attention to individual health domains may Table S1 .
ultimately yield more informative data that can be used to design interventions to improve HRQL.
Our study also has policy implications. U.S. organ allocation is based on the LAS, a system that defines "transplant Adjusted for sex, diagnosis, baseline BMI, forced expiratory volume in 1 s, 6-minute walk distance, and lung allocation score. Early: From before to 3 months after transplant; Delayed: 3 months after transplant to censoring, which is completion of 3-year follow-up, death, dropout, or the end of the study period, whichever came first. Effect estimates reflect average change in HRQL over the early or late time period.EQ5D, Euroqol 5D; MCID, minimally clinically important difference; HRQL, healthrelated quality of life. For age group 18-49, n = 56; 50-64, n = 103; 65+, n = 52. Adjusted for sex, diagnosis, baseline BMI, forced expiratory volume in 1 s, 6-minute walk distance, and lung allocation score. Early: Average change from before to 3 months after transplant. Effect estimates reflect average change in HRQL over the early or late time period. SF12-PCS, Medical Outcomes Study Short Form 12 Physical Component Summary scale; SF12-MCS, Medical Outcomes Study Short Form 12 Mental Component Summary scale; MCID, minimally clinically important difference; HRQL, health-related quality of life; AQ20-R, Airway Questionnaire 20-Revised, score reversed for ease of interpretation; EQ5D, Euroqol 5D; EQVAS, Euroqol Visual Analog Scale. For Group A, n = 36; Group B, n = 8; Group C, n = 19; Group D, n = 148. Adjusted for sex, age group, baseline BMI, forced expiratory volume in 1 s, 6-minute walk distance, and lung allocation score. Early: Average change from before to 3 months after transplant. Effect estimates reflect average change in HRQL over the early or late time period. COPD, chronic obstructive pulmonary disease; PAH, pulmonary arterial hypertension; CF, cystic fibrosis; PF, pulmonary fibrosis; SF12-PCS, Medical Outcomes Study Short Form 12 Physical Component Summary scale; SF12-MCS, Medical Outcomes Study Short Form 12 Mental Component Summary scale; AQ20-R, Airway Questionnaire 20-Revised; score reversed for ease of interpretation; EQ5D, Euroqol 5D; EQVAS, Euroqol Visual Analog Scale; HRQL, healthrelated quality of life. benefit" by 1-year survival alone. This definition, however, falls far short of reflecting the full range of clinical benefits LT strives to deliver. How patient-centered outcomes can (or should) best be incorporated to more comprehensively quantify transplant benefit remains a topic of ongoing debate (53, 54) . Depending on the metric applied, the substantial variation in the proportion of subjects failing to achieve a HRQL benefit emphasizes the importance of choosing the right instrument to quantify HRQL. As we show in this report, the influence of mortality on HRQL in instruments such as the EQ5D varies depending on the scoring approach employed. Lastly, instrument selection can be challenging since brevity may come at the expense of content validity and missed conceptual health domains of importance to lung transplant recipients. Ongoing efforts to meet this challenge may help to more fully realize the true clinical aims of LT (42, 48, 52) .
Comparing our findings to a recent large study of HRQL in patients undergoing lung transplant in Canada-a country with an allocation system different from the LAS-raises additional questions (23) . While subjects in both that cohort and ours experienced similar improvements in SF12-PCS-defined HRQL, we observed substantially smaller improvements in EQ5D and EQVAS in absolute terms. Furthermore, we observed that older patients had significantly less improvement in SF12 whereas the effect of increasing age on HRQL in the Canada cohort was negligible. Reasons for these differences are not clear but may be important. If they reflect center-specific findings, this suggests that HRQL could be improved by adopting practices from high-performing centers. Alternatively, our cohort participants were older, more likely to have pulmonary fibrosis, and included a greater proportion hospitalized at the time of transplantation. It is possible that these differences reflect trends in the United States following the adoption of the LAS (7, 8) . Indeed, in the United States, the transplant surgery hospitalization now exceeds 1 month for 25% of recipients and over 50% are discharged to places other than home without skilled support (e.g. skilled nursing facilities) (7) . This morbidity could plausibly affect HRQL measures that emphasize pain, functional status, mental health, or one's overall state of wellbeing. If this is indeed the case, our findings further underscore how important assessing metrics of transplant efficacy other than 1-year survival are to fully maximizing the individual and societal benefit of LT.
The limitations of our findings should be kept in view. Our data were based on a relatively modest-sized cohort from a single center with follow-up only up to 3 years. While our study is one of the largest to focus on HRQL, its limitations in size and duration nonetheless are relevant. Indeed, only 20% of our cohort developed CLAD during the study period, which is associated with poorer HRQL. Furthermore, the instruments used to measure HRQL in our study were not developed specifically for use in LT. While some have been validated in this population, all fail to some extent to measure certain health domains important in LT recipients (18, 42, 48, 55, 56) . Although we repeatedly measured HRQL, the state or trajectory of HRQL in between sampling periods is unknown and estimates might have been different with different sampling timeframes. Also, although we considered disability as an upstream predictor of HRQL, the SF12-PCS, AQ20-R, and EQ5D all include items that do query physical functioning. Thus, the constructs of impairment, disability, and HRQL are difficult to completely disentangle. Notably, changes in SF12-MCS were small relative to the other HRQL measures. Although our findings are consistent with prior literature (54), it is not clear whether this is attributable to high baseline scores in our cohort at or near the population norm, insensitivity of the instrument as a mental health measure, or emergence of incident problems such as depression and anxiety after transplant. Finally, our modeling approach to address survivorship bias is most relevant for patient-specific clinical decision making and counseling (e.g. "If you survive LT, you might reasonably expect your HRQL to be X at 1 year, Y at 2 years, and Z at 3 years"). This approach, however, limits our ability to provide estimates on the effect of LT on population-level HRQL.
Counterbalancing these limitations are the notable strengths of our approach. By quantifying HRQL before and repeatedly after LT for up to 3 years of follow-up, performing multivariate adjustments, evaluating HRQL across several conceptual health domains, explicitly attempting to account for selection and survivorship bias, and limiting dropout, we were able to address important limitations in the existing literature (8, 42) . We also provided effect estimates of the effect of LT across clinically relevant age and diagnostic groups, novel insights into determinants of change in HRQL after transplantation, and findings on differences in HRQL benefit depending on the instrument employed. Most saliently, our study population reflects the types of patients undergoing LT today.
In summary, our study provides contemporary evidence that LT in the LAS era affords adults with advanced lung disease large and durable improvements in HRQL across age groups and diagnoses. These improvements are largely mediated by amelioration of disabilities affecting Valued Life Activities. Despite these gains, a notable subset of patients appears to be left behind in improved HRQL. Multipronged and multicenter efforts to identify valid and patient-centered metrics of assessing transplant efficacy will help the lung transplant community maintain its focus on the outcomes that matter most to patients and society.
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